# CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

> **NCT05105867** · EARLY_PHASE1 · UNKNOWN · sponsor: **920th Hospital of Joint Logistics Support Force of People's Liberation Army of China** · enrollment: 15 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Relapsed or Refractory B-cell Non-hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Anti-CD19 Universal CAR-T Cells injection

## Key facts

- **NCT ID:** NCT05105867
- **Lead sponsor:** 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-29
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-11-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-05-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05105867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05105867, "CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05105867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*